Cellectis (CLLS) Raised to “Hold” at BidaskClub

BidaskClub upgraded shares of Cellectis (NASDAQ:CLLS) from a sell rating to a hold rating in a research note published on Saturday.

Several other research firms have also recently issued reports on CLLS. Zacks Investment Research cut shares of Cellectis from a buy rating to a hold rating in a research report on Tuesday, July 10th. Oppenheimer boosted their price objective on shares of Cellectis from $40.00 to $44.00 and gave the company an outperform rating in a research report on Tuesday, June 12th. Barclays started coverage on shares of Cellectis in a research report on Monday, July 16th. They issued an overweight rating and a $50.00 price objective for the company. Finally, ValuEngine raised shares of Cellectis from a hold rating to a buy rating in a research report on Tuesday, September 18th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $49.20.

Cellectis stock opened at $27.50 on Friday. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -9.89 and a beta of 1.84. Cellectis has a 1 year low of $22.62 and a 1 year high of $38.85.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.45. The company had revenue of $8.34 million during the quarter, compared to analysts’ expectations of $9.43 million. Cellectis had a negative net margin of 281.38% and a negative return on equity of 25.46%. As a group, equities research analysts anticipate that Cellectis will post -2.15 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in CLLS. FMR LLC lifted its position in shares of Cellectis by 18.0% in the 2nd quarter. FMR LLC now owns 4,240,010 shares of the biotechnology company’s stock worth $119,949,000 after purchasing an additional 647,164 shares during the period. Nexthera Capital LP purchased a new stake in shares of Cellectis in the 1st quarter worth approximately $10,485,000. BlackRock Inc. lifted its position in shares of Cellectis by 259.7% in the 2nd quarter. BlackRock Inc. now owns 443,713 shares of the biotechnology company’s stock worth $12,552,000 after purchasing an additional 320,340 shares during the period. Laurion Capital Management LP purchased a new stake in shares of Cellectis in the 2nd quarter worth approximately $5,658,000. Finally, ARK Investment Management LLC lifted its position in shares of Cellectis by 178.8% in the 2nd quarter. ARK Investment Management LLC now owns 244,263 shares of the biotechnology company’s stock worth $6,910,000 after purchasing an additional 156,666 shares during the period. 27.10% of the stock is owned by hedge funds and other institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).

Featured Story: Conference Calls and Individual Investors

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply